Quintiles IMS

Articles

A recent pharmaphorum webinar brought four experts together to discuss the future of market access for specialist medicines in the UK.

News

argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.